METFORMIN TABLET

Land: Kanada

Sprache: Englisch

Quelle: Health Canada

Wirkstoff:

METFORMIN HYDROCHLORIDE

Verfügbar ab:

MYLAN PHARMACEUTICALS ULC

ATC-Code:

A10BA02

INN (Internationale Bezeichnung):

METFORMIN

Dosierung:

500MG

Darreichungsform:

TABLET

Zusammensetzung:

METFORMIN HYDROCHLORIDE 500MG

Verabreichungsweg:

ORAL

Einheiten im Paket:

100/500

Verschreibungstyp:

Prescription

Therapiebereich:

BIGUANIDES

Produktbesonderheiten:

Active ingredient group (AIG) number: 0101773001; AHFS:

Berechtigungsstatus:

CANCELLED POST MARKET

Berechtigungsdatum:

2012-10-19

Fachinformation

_ _
_Product Monograph – -Metformin _
_Page 1 _
PRODUCT MONOGRAPH
PR
METFORMIN
(METFORMIN HYDROCHLORIDE)
TABLETS 500 AND 850 MG
BP
THERAPEUTIC CLASSIFICATION
ORAL ANTIHYPERGLYCEMIC AGENT
Mylan Pharmaceuticals ULC
85 Advance Road
Etobicoke, ON
Canada
M8Z 2S6
Control#: 141657
DATE OF PREPARATION:
September 28, 2010
_ _
_Product Monograph –Metformin _
_Page 2_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION........................................................ 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL
USE.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
3
WARNINGS AND
PRECAUTIONS.................................................................................
4
ADVERSE
REACTIONS.................................................................................................
10
DRUG INTERACTIONS
.................................................................................................
11
DOSAGE AND
ADMINISTRATION.............................................................................
13
OVERDOSAGE
...............................................................................................................
14
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 15
STORAGE AND
STABILITY.........................................................................................
15
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 15
PART II: SCIENTIFIC INFORMATION
...............................................................................
17
PHARMACEUTICAL
INFORMATION.........................................................................
17
CLINICAL
TRIALS.........................................................................................................
18
DETAILED
PHARMACOLOGY.